News

Find out about our current activities

Click on the news below to find out more about our current activities and media coverage.

InSphero Announces Collaboration with NIH National Center for Advancing Translational Sciences (NCATS)

InSphero Announces Collaboration with NIH National Center for Advancing Translational Sciences (NCATS)

Joint study will accelerate development of physiologically relevant 3D models for anti-cancer drug screening.  PDF Version

 

Schlieren, Switzerland -  May 03, 2017  InSphero AG today announced a collaboration with the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to identify anti-cancer agents with cytotoxic activity in 3D tumor models. In this joint project, NCATS will use patient-derived xenograft (PDX) tumor microtissues, provided by InSphero in its 384 well platform, to screen a library of anti-cancer agents for anti-tumor efficacy using assays that measure cell proliferation, tissue integrity, and tissue size.

“For cancer drug discovery, it is of critical importance to have models that are physiologically relevant,” says InSphero Chief Technology Officer and Co-founder Jens M. Kelm, Ph.D. “3D microtissues models provide a more accurate reflection of the tumor and its extracellular environment.” The latest generation of customizable 3D tumor microtissue models available from InSphero also capture the heterogeneity of tumor cell populations, making them ideal for investigating special tumor cell sub-populations called cancer stem cells (CSCs) or tumor-initiating cells. These cells have self-renewal potential and are thought to drive tumor formation and metastasis. CSCs appear to be resistant to current chemotherapy and radiation-therapy treatments that produce cancer recurrence, thus there is a heightened interest among oncologists to be able to screen therapeutic agents that target CSCs and other tumor cell sub-populations.

“To unlock the full potential of more physiologically relevant models to fosterfor drug development we need to be able to integrate 3D cancer models into the drug screening process as early as possible,” says Dr. Kelm. InSphero will work closely with researchers at NCATS to evaluate how PDX-derived tumor microtissues can be applied in primary and secondary screening campaigns using small to mid-size compound libraries.

“Our project with InSphero is yet another example of how NCATS fosters collaborations to explore novel technologies that carry the promise to accelerate discovery of molecular therapeutic agents across multiple disease areas,” says Anton Simeonov, Ph.D., acting deputy scientific director of NCATS’ Division of Pre-Clinical Innovation.

For more information about NCATS, visit https://ncats.nih.gov.

For more information about InSphero, visit www.insphero.com

InSphero contacts

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Patrick Guye
Chief Scientific Officer
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of organotypic 3D cell culture models. The company’s patented technologies include the 3D Select™ Process (pending) and scaffold-free 3D cell culture plates that enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, and tumors. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictive power at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with several national and international awards.

Follow us on Twitter and and LinkedIn.

Image

insphero logo


InSphero Announces Agreement with Pfizer to Develop Novel Assays for Predicting Drug-induced Liver Injury

InSphero Announces Agreement with Pfizer to Develop Novel Assays for Predicting Drug-induced Liver Injury

Research effort will use InSphero 3D InSight™ Human Liver Microtissues to develop novel assays to predict and evaluate certain mechanisms that cause drug-induced liver injury (DILI). PDF Vesion

Schlieren, Switzerland - April 27, 2017

InSphero AG, the leading supplier of assay-ready 3D cell culture models for accelerating drug discovery and development, has entered into an agreement with Pfizer Inc. (NYSE:PFE), one of the world’s premier biopharmaceutical companies, to develop a novel predictive toxicology assay using InSphero 3D InSight™ Human Liver Microtissues. This novel mechanistic in vitro assay will aim to leverage the enhanced sensitivity and longevity of InSphero 3D liver models that may allow for the multiplexing of several endpoints to help detect and predict mechanisms of drug toxicity.

InSphero CEO and co-founder, Dr. Jan Lichtenberg, says, “Our 3D liver models enable researchers to better predict potential toxicity and side-effects using more biologically relevant cell based assays. These models may also help reduce dependency on animal models, which add significant cost, delay time to market, and often fail to accurately reflect how humans will respond to a drug. We already have a long-standing relationship with Pfizer and this new agreement will enable the development of assays with potentially even greater utility and predictive power for Pfizer’s early drug development."

Dr. Simon Messner, who will lead the project for InSphero adds, “The longevity and organotypic nature of 3D InSight™ Human Liver Microtissues highly correlates to that of native liver, exhibiting appropriate cellular organization, cytochrome P450 enzyme responsiveness, and metabolic functionality. Using this 3D model could result in improved accuracy and precision by which certain DILI mechanisms are predicted in vitro.”

The agreement commences in April 2017 and involves InSphero scientists in the USA (Brunswick, ME) and Schlieren (Switzerland) facilities, with input from Pfizer scientists.

For more information about InSphero, visit www.insphero.com

InSphero contacts

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jan Lichtenberg
Chief Executive Officer, Co-founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

About InSphero

InSphero sets the standard for in vitro testing of novel drugs in the pharmaceutical and biotechnology industry with comprehensive solutions that provide greater confidence in decision making. Its robust and highly physiologically relevant suite of 3D InSight™ Microtissues and Services are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. InSphero patent-pending technologies and methods enable large-scale, reproducible production of scaffold-free 3D microtissues (spheroids) driven solely by cellular self-assembly. The company specializes in delivering assay-ready and custom 3D models derived from liver, pancreas, and tumor tissues, to provide unrivalled biological insight into liver toxicology, metabolic diseases (e.g., diabetes and liver diseases), and oncology (with a focus on immuno-oncology). All InSphero microtissues are thoroughly validated to ensure the highest quality, certified for use in a variety of assays, and shipped globally to customers in a patented, easy-to-use spheroid-optimized platform, ready for research. Field application scientists and research staff with expertise in working with 3D models help ensure efficient integration and onsite training as needed. For customers who prefer an outsourcing strategy with fast turnaround, InSphero also offers contract research services utilizing their 3D microtissue models.

InSphero 3D InSight™ solutions drive significant findings in peer-reviewed journals, through collaborative industry initiatives such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with several national and international awards.

Follow us on Twitter and and LinkedIn.

 

Image

Microtissue            insphero logo

 

NIH/NCATS and InSphero Host Inaugural 3D Tumor Model Standards Working Group at AACR 2017

NIH/NCATS and InSphero Host Inaugural 3D Tumor Model Standards Working Group at AACR 2017

Establishing standards for next-generation tumor models to benefit drug discovery and broader research community primary objective of new group. PDF Vesion

Schlieren, Switzerland - April 18, 2017

The inaugural meeting of the 3D Standards Working Group was held during the American Association of Cancer Research (AACR) Annual Meeting in Washington, DC, on Saturday, April 1.  Organized and hosted by the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health, and InSphero AG, the meeting drew representatives from academic institutions, pharmaceutical and life sciences industries, as well as government agencies, to discuss the use of 3D cancer models within drug discovery campaigns, and review biological and technical requirements needed for the next generation of high-throughput screening-compatible (HTS) models.

"There is a growing need for in vitro 3D tumor models that mimic in vivo tumor physiology for more efficient cancer drug discovery,” says InSphero Chief Scientific Officer Dr. Patrick Guye. “We sought to bring together key opinion leaders in academia, industry and government to develop guidelines that we believe are critical to establish 3D tumor models as a highly predictive platform for therapeutic drug development assays.” The group plans to publish its findings and recommendations for developing and using 3D tumor models for drug development, with the intent to make the best consensus information available to the broader research community.

“We made tremendous progress during this kickoff meeting,” says Dr. Madhu Lal Nag, Head of the Trans NIH RNAi Facility at NCATS. “We not only discussed where we stand today, with regard to developing advanced 3D models that capture the complexity of the tumor microenvironment, but also delved into needs for standardized nomenclature, benchmarking, improved model predictivity, and multiparametric readouts.” Going forward, the group plans to meet quarterly by teleconference and in person during future conferences, such as AACR, which most members of the working group attend.

For more information about NCATS, visit https://ncats.nih.gov.

For more information about InSphero, visit www.insphero.com

InSphero contacts

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Patrick Guye
Chief Scientific Officer
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

About InSphero

InSphero sets the standard for in vitro testing of novel drugs in the pharmaceutical and biotechnology industry with comprehensive solutions that provide greater confidence in decision making. Its robust and highly physiologically relevant suite of 3D InSight™ Microtissues and Services are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. InSphero patent-pending technologies and methods enable large-scale, reproducible production of scaffold-free 3D microtissues (spheroids) driven solely by cellular self-assembly. The company specializes in delivering assay-ready and custom 3D models derived from liver, pancreas, and tumor tissues, to provide unrivalled biological insight into liver toxicology, metabolic diseases (e.g., diabetes and liver diseases), and oncology (with a focus on immuno-oncology). All InSphero microtissues are thoroughly validated to ensure the highest quality, certified for use in a variety of assays, and shipped globally to customers in a patented, easy-to-use spheroid-optimized platform, ready for research. Field application scientists and research staff with expertise in working with 3D models help ensure efficient integration and onsite training as needed. For customers who prefer an outsourcing strategy with fast turnaround, InSphero also offers contract research services utilizing their 3D microtissue models.

InSphero 3D InSight™ solutions drive significant findings in peer-reviewed journals, through collaborative industry initiatives such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with several national and international awards.

Follow us on Twitter and and LinkedIn.

 

Image

insphero logo

 

News Archive

 

Company video

company-video-inspheor